RedHill Biopharma Shareholders Approve All Resolutions
Ticker: RDHL · Form: 6-K · Filed: Sep 18, 2024 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Sep 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
RedHill Biopharma AGM: Shareholders OK'd everything proposed. Bullish signal.
AI Summary
RedHill Biopharma Ltd. held its Annual General Meeting of Shareholders on September 18, 2024, where all proposed resolutions were approved. The company is a foreign private issuer and files annual reports under Form 20-F.
Why It Matters
Shareholder approval of all resolutions at the AGM indicates continued support for the company's management and strategic direction.
Risk Assessment
Risk Level: low — This filing is routine and reports on the outcome of a shareholder meeting, with no new financial or operational risks introduced.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- September 18, 2024 (date) — Annual General Meeting date
FAQ
What type of form is RedHill Biopharma Ltd. filing?
RedHill Biopharma Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
When was the Annual General Meeting of Shareholders held?
The Annual General Meeting of Shareholders was held on September 18, 2024.
What was the outcome of the proposed resolutions at the AGM?
All of the proposed resolutions at the Annual General Meeting of Shareholders were approved.
Under which form does RedHill Biopharma Ltd. file its annual reports?
RedHill Biopharma Ltd. files its annual reports under Form 20-F.
Where is RedHill Biopharma Ltd.'s principal executive office located?
RedHill Biopharma Ltd.'s principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 8.6 · Accepted 2024-09-18 09:00:09
Filing Documents
- zk2432046.htm (6-K) — 14KB
- 0001178913-24-003085.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: September 18, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer